New Patients


What is Lu-177 DOTA-Octreotate treatment?

Lutetium-177 is a radioactive substance that can be added to a carrier called DOTAOctreotate. Once in your body, the Lu-177 DOTA-Octreotate attaches well to certain receptors (called somatostatin-receptor) which are almost exclusively found on neuroendocrine tumours. The radioactive Lu-177 then destroys these cancerous cells.

This treatment is known to be effective in gastroenteropancreatic (GEP) neuroendocrine tumours, such as:

  • Intestinal carcinoids
  • Tumours of the pancreas
  • Bronchial carcinoids

This treatment can also be used for other slow growing tumours, such as:

  • Paraganglioma
  • Phaeochromocytoma
  • Carotid body tumours
  • Medullary thyroid cancer
  • Thymic tumours

The team looking after you at the WELLNET Unit will consist of a team of neuroendocrine tumour specialists including doctors, clinical nurse specialists and nuclear medicine physicians.

Associated Bodies:

  • The Wellington Hospital Logo
  • ENets Logo